How much fat is necessary to optimize lumefantrine oral bioavailability?
BACKGROUND: Artemether-lumefantrine (AL) is the only fixed, artemisinin-based combination antimalarial drug which is registered internationally and deployed on a large scale. Absorption of the hydrophobic lipophilic lumefantrine component varies widely between individuals and is greatly increased b...
主要な著者: | Ashley, E, Stepniewska, K, Lindegårdh, N, Annerberg, A, Kham, A, Brockman, A, Singhasivanon, P, White, N, Nosten, F |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2007
|
類似資料
-
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
著者:: Tarning, J, 等
出版事項: (2009) -
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
著者:: Ashley, E, 等
出版事項: (2007) -
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria
著者:: Ashley, E, 等
出版事項: (2007) -
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
著者:: Mcgready, R, 等
出版事項: (2006) -
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
著者:: McGready, R, 等
出版事項: (2009)